

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2007 (25.10.2007)

PCT

(10) International Publication Number
WO 2007/119055 A1

(51) International Patent Classification:

C07D 239/90 (2006.01) A61K 31/517 (2006.01)
C07D 239/88 (2006.01) A61P 35/00 (2006.01)
C07D 401/12 (2006.01)

[US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US).

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(21) International Application Number:

PCT/GB2007/001389

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 17 April 2007 (17.04.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/745,038 18 April 2006 (18.04.2006) US

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except MG, US): ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, Greater London, London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): AQUILA, Brian [US/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). LYNE, Paul [IE/US]; AstraZeneca R & D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). PONTZ, Timothy

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM



(57) Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

WO 2007/119055 A1

QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their
5 anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

10 The classical Ras, Raf, MAP protein kinase/extracellular signal –regulated kinase kinase (MEK), extracellular signal –regulated kinase (ERK) pathway plays a central role in the regulation of a variety of cellular functions dependent upon cellular context, including cellular proliferation, differentiation, survival, immortalization and angiogenesis (reviewed in
15 Peyssonnaud and Eychene, *Biology of the Cell*, 2001, 93,3-62). In this pathway, Raf family members are recruited to the plasma membrane upon binding to guanosine triphosphate (GTP) loaded Ras resulting in the phosphorylation and activation of Raf proteins. Activated Rafs then phosphorylate and activate MEKs, which in turn phosphorylate and activate ERKs. Upon activation, ERKs translocate from the cytoplasm to the nucleus resulting in the phosphorylation and regulation of activity of transcription factors such as Elk-1 and Myc.

20 The Ras/Raf/MEK/ERK pathway has been reported to contribute to the tumorigenic phenotype by inducing immortalisation, growth factor-independent growth, insensitivity to growth-inhibitory signals, ability to invade and metastasis, stimulating angiogenesis and inhibition of apoptosis (reviewed in Kolch et al., *Exp. Rev. Mol. Med.*, 2002, 25 April, <http://www.expertreviews.org/02004386h.htm>). In fact, ERK phosphorylation is enhanced in
25 approximately 30% of all human tumours (Hoshino et al., *Oncogene*, 1999, 18, 813-822). This may be a result of overexpression and/or mutation of key members of the pathway.


Three Raf serine/threonine protein kinase isoforms have been reported Raf-1 /c-Raf, B-Raf and A-Raf (reviewed in Mercer and Pritchard, *Biochim. Biophys. Acta*, 2003, 1653, 25-40), the genes for which are thought to have arisen from gene duplication. All three Raf
30 genes are expressed in most tissues with high-level expression of B-Raf in neuronal tissue and A-Raf in urogenital tissue. The highly homologous Raf family members have overlapping but distinct biochemical activities and biological functions (Hagemann and Rapp, *Expt. Cell Res.* 1999, 253, 34-46). Expression of all three Raf genes is required for normal murine

- 2 -

development however both c-Raf and B-Raf are required to complete gestation. B-Raf -/- mice die at E12.5 due to vascular haemorrhaging caused by increased apoptosis of endothelial cells (Wojnowski et al., Nature Genet., 1997, 16, 293-297). B-Raf is reportedly the major isoform involved in cell proliferation and the primary target of oncogenic Ras. Activating somatic missense mutations have been identified exclusively for B-Raf, occurring with a frequency of 66% in malignant cutaneous melanomas (Davies et al., Nature, 2002, 417, 949-954) and also present in a wide range of human cancers, including but not limited to papillary thyroid tumours (Cohen et al., J. Natl. Cancer Inst., 2003, 95, 625-627), cholangiocarcinomas (Tannapfel et al., Gut, 2003, 52, 706-712), colon and ovarian cancers (Davies et al., Nature, 2002, 417, 949-954). The most frequent mutation in B-Raf (80%) is a glutamic acid for valine substitution at position 600. These mutations increase the basal kinase activity of B-Raf and are thought to uncouple Raf/MEK/ERK signalling from upstream proliferation drives including Ras and growth factor receptor activation resulting in constitutive activation of ERK. Mutated B-Raf proteins are transforming in NIH3T3 cells (Davies et al., Nature, 2002, 417, 949-954) and melanocytes (Wellbrock et al., Cancer Res., 2004, 64, 2338-2342) and have also been shown to be essential for melanoma cell viability and transformation (Hingorani et al., Cancer Res., 2003, 63, 5198-5202). As a key driver of the Raf/MEK/ERK signalling cascade, B-Raf represents a likely point of intervention in tumours dependent on this pathway.

AstraZeneca has filed certain international applications directed towards BRAf inhibitors: WO 2005/123696, WO 2006/003378, WO 2006/024834, WO 2006/024836, WO 2006/040568, WO 2006 / 067446 and WO 2006/079791. The present application is based on a class of compound which are novel BRAf inhibitors and it is expected that these compounds could possess beneficial efficacious, metabolic and / or toxicological profiles that make them particularly suitable for *in vivo* administration to a warm blooded animal, such as man.

Accordingly, the present invention provides a compound of formula (I):



(I)

wherein:

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁷;

R¹ is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, *N*-(C₁₋₆alkoxy)sulphamoyl, *N*-(C₁₋₆alkyl)-*N*-(C₁₋₆alkoxy)sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R⁸- or heterocyclyl-R⁹-; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

n is selected from 0-4; wherein the values of R¹ may be the same or different;

R² is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R¹²- or heterocyclyl-R¹³-; wherein R² may be optionally substituted on carbon by one or more R¹⁴; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

q is 0-2; wherein the values of R² may be the same or different;


X is NR¹⁶ or O;

R³ and R⁶ are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R¹⁷- or heterocyclyl-R¹⁸-; wherein R³ and R⁶ independently of each other may be optionally substituted on carbon by one or more R¹⁹; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁰;

- 4 -

R^4 , R^5 and R^{16} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, carbocyclyl, heterocyclyl, N -(C_{1-6} alkyl)carbamoyl and N,N -(C_{1-6} alkyl)carbamoyl; wherein R^4 , R^5 and R^{16} independently of each other may be optionally substituted on carbon by one or more R^{21} ;

5 m is 3; wherein the values of R^6 may be the same or different;

the bond “” between the $-NR^5-$ and $-CR^3-$ of formula (I) is either (i) a single bond wherein R^5 is as defined above, or (ii) a double bond wherein R^5 is absent;

R^{10} , R^{14} , R^{19} and R^{21} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxycarbonylamino, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{22} - or heterocyclyl- R^{23} -; wherein R^{10} , R^{14} , R^{19} and R^{21} independently of each other may be optionally substituted on
15 carbon by one or more R^{24} ; and wherein if said heterocyclyl contains an $-NH-$ moiety that nitrogen may be optionally substituted by a group selected from R^{25} ;

R^8 , R^9 , R^{12} , R^{13} , R^{17} , R^{18} , R^{22} and R^{23} are independently selected from a direct bond, $-O-$, $-N(R^{26})-$, $-C(O)-$, $-N(R^{27})C(O)-$, $-C(O)N(R^{28})-$, $-S(O)_s-$, $-SO_2N(R^{29})-$ or $-N(R^{30})SO_2-$; wherein R^{26} , R^{27} , R^{28} , R^{29} and R^{30} is hydrogen, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl and s is 0-2;

20 R^7 , R^{11} , R^{15} , R^{20} and R^{25} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R^{24} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, N -methyl- N -ethylamino, acetylamino, N -methylcarbamoyl, N -ethylcarbamoyl, N,N -dimethylcarbamoyl, N,N -diethylcarbamoyl, N -methyl- N -ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, N -methylsulphamoyl, N -ethylsulphamoyl, N,N -dimethylsulphamoyl, N,N -diethylsulphamoyl
30 or N -methyl- N -ethylsulphamoyl;
or a pharmaceutically acceptable salt thereof.

In this specification the term “alkyl” includes both straight and branched chain alkyl groups. References to individual alkyl groups such as “propyl” are specific for the straight

chain version only and references to individual branched chain alkyl groups such as 'isopropyl' are specific for the branched chain version only. For example, "C₁₋₆alkyl" includes C₁₋₄alkyl, C₁₋₃alkyl, propyl, isopropyl and *t*-butyl. A similar convention applies to other radicals, for example "phenylC₁₋₆alkyl" includes phenylC₁₋₄alkyl, benzyl, 1-phenylethyl and 2-phenylethyl. The term "halo" refers to fluoro, chloro, bromo and iodo.

Where optional substituents are chosen from "one or more" groups it is to be understood that this definition includes all substituents being chosen from one of the specified groups or the substituents being chosen from two or more of the specified groups.

A "heterocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 4-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a -CH₂- group can optionally be replaced by a -C(O)-, and a ring sulphur atom may be optionally oxidised to form the S-oxides. Examples and suitable values of the term "heterocyclyl" are morpholino, piperidyl, pyridyl, pyranyl, pyrrolyl, pyrazolyl, isothiazolyl, indolyl, quinolyl, thienyl, 1,3-benzodioxolyl, thiadiazolyl, piperazinyl, thiazolidinyl, pyrrolidinyl, thiomorpholino, pyrrolinyl, homopiperazinyl, 3,5-dioxapiperidinyl, tetrahydropyranyl, imidazolyl, pyrimidyl, pyrazinyl, pyridazinyl, isoxazolyl, *N*-methylpyrrolyl, 4-pyridone, 1-isoquinolone, 2-pyrrolidone, 4-thiazolidone, pyridine-*N*-oxide and quinoline-*N*-oxide. A particular example of the term "heterocyclyl" is pyrazolyl. In one aspect of the invention a "heterocyclyl" is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, it may, unless otherwise specified, be carbon or nitrogen linked, a -CH₂- group can optionally be replaced by a -C(O)- and a ring sulphur atom may be optionally oxidised to form the S-oxides.

A "carbocyclyl" is a saturated, partially saturated or unsaturated, mono or bicyclic carbon ring that contains 3-12 atoms; wherein a -CH₂- group can optionally be replaced by a -C(O)-. Particularly "carbocyclyl" is a monocyclic ring containing 5 or 6 atoms or a bicyclic ring containing 9 or 10 atoms. Suitable values for "carbocyclyl" include cyclopropyl, cyclobutyl, 1-oxocyclopentyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, tetralinyl, indanyl or 1-oxoindanyl. A particular example of "carbocyclyl" is phenyl.

An example of "C₁₋₆alkanoyloxy" is acetoxy. Examples of "C₁₋₆alkoxycarbonyl" include methoxycarbonyl, ethoxycarbonyl, *n*- and *t*-butoxycarbonyl. Examples of "C₁₋₆alkoxy" include methoxy, ethoxy and propoxy. Examples of "C₁₋₆alkanoylamino" include formamido, acetamido and propionylamino. Examples of "C₁₋₆alkylS(O)_a wherein a is

0 to 2” include methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl. Examples of “C₁₋₆alkanoyl” include propionyl and acetyl. Examples of “N-(C₁₋₆alkyl)amino” include methylamino and ethylamino. Examples of “N,N-(C₁₋₆alkyl)₂amino” include di-N-methylamino, di-(N-ethyl)amino and

5 N-ethyl-N-methylamino. Examples of “C₂₋₆alkenyl” are vinyl, allyl and 1-propenyl. Examples of “C₂₋₆alkynyl” are ethynyl, 1-propynyl and 2-propynyl. Examples of “N-(C₁₋₆alkyl)sulphamoyl” are N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl. Examples of “N-(C₁₋₆alkyl)₂sulphamoyl” are N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl. Examples of “N-(C₁₋₆alkyl)carbamoyl” are

10 N-(C₁₋₄alkyl)carbamoyl, methylaminocarbonyl and ethylaminocarbonyl. Examples of “N,N-(C₁₋₆alkyl)₂carbamoyl” are N,N-(C₁₋₄alkyl)₂carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl. Examples of “C₁₋₆alkylsulphonyl” are mesyl, ethylsulphonyl and isopropylsulphonyl. Examples of “C₁₋₆alkylsulphonylamino” are mesylamino, ethylsulphonylamino and isopropylsulphonylamino. Examples of

15 “N-(C₁₋₆alkoxy)sulphamoyl” include N-(methoxy)sulphamoyl and N-(ethoxy)sulphamoyl. Examples of “N-(C₁₋₆alkyl)-N-(C₁₋₆alkoxy)sulphamoyl” N-(methyl)-N-(methoxy)sulphamoyl and N-(propyl)-N-(ethoxy)sulphamoyl.

A suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for

20 example, an acid-addition salt with, for example, an inorganic or organic acid, for example hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid. In addition a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an

25 organic base which affords a physiologically-acceptable cation, for example a salt with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Some compounds of the formula **(I)** may have chiral centres and/or geometric isomeric centres (E- and Z- isomers), and it is to be understood that the invention

30 encompasses all such optical, diastereoisomers and geometric isomers that possess B-Raf inhibitory activity. The invention further relates to any and all tautomeric forms of the compounds of the formula **(I)** that possess B-Raf inhibitory activity.

It is also to be understood that certain compounds of the formula (I) can exist in solvated as well as unsolvated forms such as, for example, hydrated forms. It is to be understood that the invention encompasses all such solvated forms which possess B-Raf inhibitory activity.

5 Particular values of variable groups are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

Ring A is carbocyclyl.

Ring A is heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that
10 nitrogen may be optionally substituted by a group selected from R⁷.

Ring A is carbocyclyl or heterocyclyl.

Ring A is phenyl.

Ring A is phenyl, pyrimidinyl or pyridyl.

Ring A is phenyl, pyrimidin-4-yl or pyrid-4-yl.

15 R¹ is a substituent on carbon and is selected from halo or C₁₋₆alkyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

R¹⁰ is halo or cyano.

R¹ is a substituent on carbon and is selected from halo or C₁₋₆alkyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

20 R¹⁰ is halo, cyano or heterocyclyl-R²³-; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁵;

R²³ is a direct bond; and

R²⁵ is C₁₋₆alkyl.

R¹ is a substituent on carbon and is selected from fluoro, chloro, methyl or isopropyl;
25 wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

R¹⁰ is fluoro or cyano.

R¹ is a substituent on carbon and is selected from fluoro, chloro, methyl, ethyl or isopropyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

R¹⁰ is fluoro, cyano or piperazinyl-R²³-; wherein said piperazinyl may be optionally
30 substituted on nitrogen by a group selected from R²⁵;

R²³ is a direct bond; and

R²⁵ is methyl.

- 8 -

R¹ is a substituent on carbon and is selected from fluoro, chloro, trifluoromethyl or 1-methyl-1-cyanoethyl.

R¹ is a substituent on carbon and is selected from fluoro, chloro, trifluoromethyl, 1,1-difluoroethyl, 1-methylpiperazin-4-ylmethyl or 1-methyl-1-cyanoethyl.

5 R¹ is a substituent on carbon and is selected from halo or C₁₋₆alkyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

R¹⁰ is halo.

R¹ is a substituent on carbon and is selected from fluoro, chloro or methyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein

10 R¹⁰ is fluoro.

R¹ is a substituent on carbon and is selected from fluoro, chloro or trifluoromethyl.

n is selected from 0-2; wherein the values of R¹ may be the same or different.

n is 0.

n is 1.

15 n is 2; wherein the values of R¹ may be the same or different.

n is 1 or 2; wherein the values of R¹ may be the same or different.

Ring A and (R¹)_n together form 2-(trifluoromethyl)-4-pyridyl,

2-fluoro-3-(trifluoromethyl)phenyl, 3-(1,1-difluoroethyl)phenyl,

3-(1-cyano-1-methyl-ethyl)phenyl, 3-(trifluoromethyl)phenyl,

20 3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl,

3-fluoro-5-(trifluoromethyl)phenyl, 4-(1-cyano-1-methyl-ethyl)phenyl,

4-chloro-3-(trifluoromethyl)phenyl, 4-fluoro-3-(trifluoromethyl)phenyl or

6-(trifluoromethyl)pyrimidin-4-yl.

R² is C₁₋₆alkyl.

25 R² is methyl.

q is 0 or 1.

q is 0.

X is NR¹⁶.

X is O.

30 X is NR¹⁶ or O; wherein R¹⁶ is hydrogen.

R³ and R⁶ are hydrogen.

R⁴ is selected from hydrogen and C₁₋₆alkyl; wherein R⁴ may be optionally substituted on carbon by one or more R²¹;

R^{21} is selected from amino, C_{1-6} alkoxycarbonylamino or heterocyclyl- R^{23} -; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{25} ;

R^{23} is a direct bond;

5 R^{25} is C_{1-6} alkyl.

R^4 is C_{1-6} alkyl.

R^4 is selected from hydrogen and C_{1-6} alkyl; wherein R^4 may be optionally substituted on carbon by one or more R^{21} ;


10 R^{21} is selected from amino, *t*-butoxycarbonylamino or piperidinyl- R^{23} -; and wherein said piperidinyl may be optionally substituted on nitrogen by a group selected from R^{25} ;


R^{23} is a direct bond;

R^{25} is methyl.

R^4 is methyl.

15 R^4 is methyl, 3-aminopropyl, 1-methylpiperidin-3-ylmethyl or 3-(*t*-butoxycarbonylamino)propyl.

the bond “” between the - NR^5 - and - CR^3 - of formula (I) is a single bond wherein R^5 is as defined above.

the bond “” between the - NR^5 - and - CR^3 - of formula (I) is a double bond wherein R^5 is absent.

20 Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

Ring A is carbocyclyl;

R^1 is a substituent on carbon and is selected from halo or C_{1-6} alkyl; wherein R^1 may be optionally substituted on carbon by one or more R^{10} ;

25 n is 2; wherein the values of R^1 may be the same or different;


q is 0;

X is O;

R^3 and R^6 are hydrogen;

m is 3; wherein the values of R^6 may be the same or different;

30 R^4 is C_{1-6} alkyl;

the bond “” between the - NR^5 - and - CR^3 - of formula (I) is a double bond wherein R^5 is absent;

- 10 -

R¹⁰ is halo;

or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula **(I)** (as depicted above) wherein:

5 Ring A is phenyl, pyrimidinyl or pyridyl;

R¹ is a substituent on carbon and is selected from halo or C₁₋₆alkyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰;

n is 1 or 2; wherein the values of R¹ may be the same or different;

R² is C₁₋₆alkyl;


10 q is 0 or 1;

X is NR¹⁶ or O; wherein R¹⁶ is hydrogen;

R³ and R⁶ are hydrogen;

m is 3; wherein the values of R⁶ may be the same or different;

15 R⁴ is selected from hydrogen and C₁₋₆alkyl; wherein R⁴ may be optionally substituted on carbon by one or more R²¹;

the bond “” between the -NR⁵- and -CR³- of formula **(I)** is a double bond wherein R⁵ is absent;

R¹⁰ is halo, cyano or heterocyclyl-R²³-; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁵;

20 R²¹ is selected from amino, C₁₋₆alkoxycarbonylamino or heterocyclyl-R²³-; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁵;

R²³ is a direct bond;

R²⁵ is C₁₋₆alkyl;

25 or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula **(I)** (as depicted above) wherein:

Ring A is phenyl;

R¹ is a substituent on carbon and is selected from fluoro, chloro or trifluoromethyl;

30 n is 2; wherein the values of R¹ may be the same or different;

q is 0;


X is O;

R³ and R⁶ are hydrogen;

- 11 -

m is 3; wherein the values of R⁶ may be the same or different;

R⁴ is methyl;

the bond “” between the -NR⁵- and -CR³- of formula (I) is a double bond wherein R⁵ is absent;

5 or a pharmaceutically acceptable salt thereof.

Therefore in a further aspect of the invention there is provided a compound of formula (I) (as depicted above) wherein:

Ring A is phenyl, pyrimidin-4-yl or pyrid-4-yl;

R¹ is a substituent on carbon and is selected from fluoro, chloro, trifluoromethyl,

10 1,1-difluoroethyl, 1-methylpiperazin-4-ylmethyl or 1-methyl-1-cyanoethyl;

n is 1 or 2; wherein the values of R¹ may be the same or different;

R² is methyl;

q is 0 or 1;


X is NH or O;

15 R³ and R⁶ are hydrogen;

m is 3; wherein the values of R⁶ may be the same or different;

R⁴ is methyl, 3-aminopropyl, 1-methylpiperidin-3-ylmethyl or

3-(*t*-butoxycarbonylamino)propyl;

the bond “” between the -NR⁵- and -CR³- of formula (I) is a double bond wherein

20 R⁵ is absent;


or a pharmaceutically acceptable salt thereof.

In another aspect of the invention, preferred compounds of the invention are any one of the Examples or a pharmaceutically acceptable salt thereof.

Another aspect of the present invention provides a process for preparing a compound

25 of formula (I) or a pharmaceutically acceptable salt thereof which process (wherein variable are, unless otherwise specified, as defined in formula (I)) comprises of:


Process a) reacting an amine of the formula (II):




(II)

- 12 -

with an isocyanato of formula (III):




(III)

Process b) reacting a compound of formula (IV):

5


(IV)

with an compound of formula (V):




(V)

10 wherein L is a displaceable group;

Process c) reacting a compound of formula (VI):

(VI)

wherein L is a displaceable group; with an compound of formula (VII):



15

(VII)


- 13 -

Process d) for compounds of formula (I) wherein R⁴ is not hydrogen; reacting a compound of formula (I) wherein R⁴ is hydrogen with a compound of formula (VIII):



5 wherein L is a displaceable group and R⁴ is not hydrogen;

Process e) for compounds of formula (I) wherein X is NR¹⁶ and R¹⁶ is -CH₂-C₂₋₆alkyl optionally substituted on carbon by one or more R²¹; reacting a compound of formula (I) wherein X is NR¹⁶ and R¹⁶ is hydrogen with a compound of formula (IX):



10

(IX)

wherein R¹⁶ is C₁₋₅alkyl optionally substituted on carbon by one or more R²¹;

Process f) for compounds of formula (I) wherein X is NR¹⁶ and R¹⁶ is not hydrogen; reacting a compound of formula (I) wherein X is NR¹⁶ and R¹⁶ is hydrogen with a compound of formula (X):


15



(X)

wherein L is a displaceable group and R¹⁶ is not hydrogen;


Process g) reacting an isocyanato of the formula (XI):



20

(XI)

with an amine of formula (XII):



(XII)

and thereafter if necessary:

- 25 i) converting a compound of the formula (I) into another compound of the formula (I);
ii) removing any protecting groups;

iii) forming a pharmaceutically acceptable salt.


L is a displaceable group, suitable values for L are for example, a halo for example a chloro or bromo.

Specific reaction conditions for the above reactions are as follows.

5 *Process a)* and *Process g)* Isocyanatos and amines may be reacted together in an appropriate solvent such as THF or DCM from temperatures of 25 °C upwards.

Suitable activated acid derivatives include acid halides, for example acid chlorides, and active esters, for example pentafluorophenyl esters. The reaction of these types of compounds with amines is well known in the art, for example they may be reacted in the
10 presence of a base, such as those described above, and in a suitable solvent, such as those described above. The reaction may conveniently be performed at a temperature in the range of -40 to 40°C.

Amines of formula (II) may be prepared according to *Scheme 1*:



15

Scheme 1


Isocyanatos of formula (XI) may be prepared by reacting a compound of formula (II) and triphosgene under standard conditions.

Compounds of formula (IIa), (III) and (XII) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in
20 the art.

Process b) and *Process c)* Compounds of formula (IV) and (V) and compounds of formula (VI) and (VII) can be reacted together by coupling chemistry utilizing an appropriate catalyst and ligand such as Pd₂(dba)₃ and BINAP respectively and a suitable base such as sodium *tert*-butoxide. The reaction usually requires thermal conditions often in the range of 80 °C to
25 100 °C.

Compounds of formula (IV) may be prepared according to *Scheme 2*:


- 15 -



Scheme 2

wherein Pg is a suitable protecting group.

Compounds of formula (VI) may be prepared according to Scheme 3:



5

Scheme 3

wherein Pg is a suitable protecting group.

Compounds of formula (IVa), (V), (VIa) and (VII) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.

Process d) Compounds of formula (I) and (VIII) can be reacted together in solvents such as DMF or CH₃CN in the presence of a base such as K₂CO₃ or Cs₂CO₃. The reaction usually requires thermal conditions in the range of 50 °C to 100 °C.

Compounds of formula (VIII) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.

Process e) Compounds of formula (I) and (IX) can be reacted by standard reductive amination chemistry utilizing an appropriate solvent such as THF, dichloroethane or CH₃CN, in a pH range of 6-8 using a reducing agent such as sodium triacetoxyborohydride or sodium cyanoborohydride. The reaction is typically accomplished at 25 °C. This reaction can also be achieved by utilizing formic acid. The reaction usually requires thermal conditions such as 70 °C.

Compounds of formula (IX) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.

Process f) Compounds of formula (I) and (X) can be reacted together in various solvents such as DMF or CH₃CN in the presence of a base such as K₂CO₃ or Cs₂CO₃. The reaction usually requires thermal conditions in the range of 50 °C to 100 °C.

25

Compounds of formula (X) are commercially available compounds, or they are known in the literature or they may be prepared by standard processes known in the art.

It will be appreciated that certain of the various ring substituents in the compounds of the present invention may be introduced by standard aromatic substitution reactions or
5 generated by conventional functional group modifications either prior to or immediately following the processes mentioned above, and as such are included in the process aspect of the invention. Such reactions and modifications include, for example, introduction of a substituent by means of an aromatic substitution reaction, reduction of substituents, alkylation of substituents and oxidation of substituents. The reagents and reaction conditions for such
10 procedures are well known in the chemical art. Particular examples of aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts
15 conditions; and the introduction of a halogeno group. Particular examples of modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.

It will also be appreciated that in some of the reactions mentioned herein it may be
20 necessary/desirable to protect any sensitive groups in the compounds. The instances where protection is necessary or desirable and suitable methods for protection are known to those skilled in the art. Conventional protecting groups may be used in accordance with standard practice (for illustration see T.W. Green, Protective Groups in Organic Synthesis, John Wiley and Sons, 1991). Thus, if reactants include groups such as amino, carboxy or hydroxy it may
25 be desirable to protect the group in some of the reactions mentioned herein.

A suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxy carbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or *t*-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl. The deprotection
30 conditions for the above protecting groups necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or alkoxy carbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an acyl group such

as a *t*₃butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with
5 a Lewis acid for example boron tris(trifluoroacetate). A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.

A suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an
10 arylmethyl group, for example benzyl. The deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group. Thus, for example, an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide. Alternatively an arylmethyl group such as a benzyl group may be removed, for example, by
15 hydrogenation over a catalyst such as palladium-on-carbon.

A suitable protecting group for a carboxy group is, for example, an esterifying group, for example a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a *t*-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic
20 acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.

The protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.

As stated hereinbefore the compounds defined in the present invention possesses
25 anti-cancer activity which is believed to arise from the B-Raf inhibitory activity of the compound. These properties may be assessed, for example, using the procedure set out below:-

B-Raf in vitro ELISA assay

Activity of human recombinant, purified wild type His-B-Raf protein kinase was
30 determined in vitro using an enzyme-linked immunosorbent assay (ELISA) assay format, which measures phosphorylation of the B-Raf substrate, human recombinant, purified His-derived (detagged) MEK1. The reaction utilized 2.5nM B-Raf, 0.15μM MEK1 and 10μM adenosine triphosphate (ATP) in 40mM *N*-(2-hydroxyethyl)piperazine-*N'*-(2-ethanesulfonic

- 18 -

acid hemisodium salt (HEPES), 5mM 1,4-dithio-DL-threitol (DTT), 10mM MgCl₂, 1mM ethylenediaminetetraacetic acid (EDTA) and 0.2M NaCl (1x HEPES buffer), with or without compound at various concentrations, in a total reaction volume of 25µl in 384 well plates. B-Raf and compound were preincubated in 1x HEPES buffer for 1 hour at 25 °C. Reactions were initiated with addition of MEK1 and ATP in 1x HEPES buffer and incubated at 25 °C for 50 minutes and reactions stopped by addition of 10µl 175mM EDTA (final concentration 50mM) in 1 x HEPES buffer. 5µl of the assay mix was then diluted 1:20 into 50mM EDTA in 1 x HEPES buffer, transferred to 384 well black high protein binding plates and incubated for 12 h at 4 °C. Plates were washed in tris buffered saline containing 0.1% Tween20 (TBST), blocked with 50µl Superblock (Pierce) for 1 hour at 25 °C , washed in TBST, incubated with 50µl rabbit polyclonal anti-phospho-MEK antibody (Cell Signaling) diluted 1:1000 in TBS for 2 h at 25 °C , washed with TBST, incubated with 50µl goat anti-rabbit horseradish peroxidase -linked antibody (Cell Signaling) diluted 1:2000 in TBS for 1 hour at 25 °C and washed with TBST. 50µl of fluorogenic peroxidase substrate (Quintablu - Pierce) was added and following incubation for 45-60 mins, 50µl QuintabluSTOP (Pierce) was added. Blue fluorescent product was detected at excitation 325 nm and emission 420 nm using a TECAN Ultra plate reader. Data was graphed and IC₅₀s calculated using Excel Fit (Microsoft).

B-Raf in-vitro AlphaScreen assay

Activity of purified full length His-tagged Mutant B-Raf (V600E) enzyme (MT B-Raf) was determined in-vitro using an Amplified Luminescent Proximity Homogeneous Assay (ALPHA) (Perkin Elmer, MA), which measures phosphorylation of the MT B-Raf substrate, biotinylated HIS-MEK-AVI (PLAZA internal database, construct #pAZB0141), as described below. MT B-Raf was expressed in insect cells and affinity purified by Ni⁺² agarose followed by Q-Sepharose chromatography. Typical yield was 1.08 mg/ml at >90% purity. The phosphorylation of the MT B-Raf substrate in the presence and absence of the compound of interest was determined. Briefly, 5µl of enzyme/substrate/adenosine triphosphate (ATP) mix consisting of 0.12nM MT B-Raf, 84nM biotinylated HIS-MEK-AVI, and 24µM ATP in 1.2x buffer was preincubated with 2ul of compound for 20 minutes at 25 °C. Reactions were initiated with 5µl of Metal mix consisting of 24mM MgCl₂ in 1.2x buffer and incubated at 25 °C for 60 minutes and reactions were stopped by addition of 5µl of Detection mix consisting of 20mM HEPES, 102mM ethylenediamine tetraacetic acid, 1.65mg/ml BSA, 136mM NaCl, 3.4nM Phospho-MEK1/2 (Ser217/221) antibody (Catalog #9121, Cell Signaling Technology,

MA), 40µg/ml Streptavidin donor beads (Perkin Elmer, MA, Catalog #6760002), and 40µg/ml Protein A acceptor beads (Perkin Elmer, MA, Catalog #6760137). Plates were incubated at 25 °C for 18 hours in the dark. Phosphorylated substrate was detected by an EnVision plate reader (Perkin Elmer, MA) 680nm excitation, 520-620nm emission. Data was graphed and IC₅₀s calculated using Excel Fit (Microsoft).

When tested in the above *in vitro* AlphaScreen assay, the compounds of the present invention exhibited activity less than 30 µM. For example the following results were obtained:

Example No	IC ₅₀ (µM)
1	0.287
3	0.205
7	0.340

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore, in association with a pharmaceutically-acceptable diluent or carrier.

The composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.

In general the above compositions may be prepared in a conventional manner using conventional excipients.

The compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 1-1000 mg/kg, and this normally provides a therapeutically-effective dose. Preferably a daily dose in the range of 10-100 mg/kg is employed. However the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.

According to a further aspect of the present invention there is provided a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use in a method of treatment of the human or animal body by therapy.

We have found that the compounds defined in the present invention, or a pharmaceutically acceptable salt thereof, are effective anti-cancer agents which property is believed to arise from their B-Raf inhibitory properties. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by B-Raf, i.e. the compounds may be used to produce a B-Raf inhibitory effect in a warm-blooded animal in need of such treatment.

Thus the compounds of the present invention provide a method for treating cancer characterised by inhibition of B-Raf, i.e. the compounds may be used to produce an anti-cancer effect mediated alone or in part by the inhibition of B-Raf.

Such a compound of the invention is expected to possess a wide range of anti-cancer properties as activating mutations in B-Raf have been observed in many human cancers, including but not limited to, melanoma, papillary thyroid tumours, cholangiocarcinomas, colon, ovarian and lung cancers. Thus it is expected that a compound of the invention will possess anti-cancer activity against these cancers. It is in addition expected that a compound of the present invention will possess activity against a range of leukaemias, lymphoid malignancies and solid tumours such as carcinomas and sarcomas in tissues such as the liver, kidney, bladder, prostate, breast and pancreas. In particular such compounds of the invention are expected to slow advantageously the growth of primary and recurrent solid tumours of, for example, the skin, colon, thyroid, lungs and ovaries. More particularly such compounds of the invention, or a pharmaceutically acceptable salt thereof, are expected to inhibit the growth of those primary and recurrent solid tumours which are associated with B-Raf, especially those tumours which are significantly dependent on B-Raf for their growth and spread, including for example, certain tumours of the skin, colon, thyroid, lungs and ovaries. Particularly the compounds of the present invention are useful in the treatment of melanomas.

Thus according to this aspect of the invention there is provided a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for use as a medicament.

According to a further aspect of the invention there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for the manufacture of a medicament for the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.

According to this aspect of the invention there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined hereinbefore for the

manufacture of a medicament for the production of an anti-cancer effect in a warm-blooded animal such as man.

According to a further feature of the invention, there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined herein
5 before for the manufacture of a medicament for the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.

10 According to a further aspect of the invention there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.

According to this aspect of the invention there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined hereinbefore in the
15 production of an anti-cancer effect in a warm-blooded animal such as man.

According to a further feature of the invention, there is provided the use of a compound of the formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined herein before in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and
20 sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.

According to a further feature of this aspect of the invention there is provided a method for producing a B-Raf inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a
25 compound of formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined above.

According to a further feature of this aspect of the invention there is provided a method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula **(I)**, or a pharmaceutically acceptable salt thereof, as defined above.

30 According to an additional feature of this aspect of the invention there is provided a method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid

tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined herein before.

5 In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.

In a further aspect of the invention there is provided a pharmaceutical composition
10 which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

In a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof,
15 as defined herein before in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries in a warm-blooded
20 animal such as man.

The B-Raf inhibitory treatment defined hereinbefore may be applied as a sole therapy or may involve, in addition to the compound of the invention, conventional surgery or radiotherapy or chemotherapy. Such chemotherapy may include one or more of the following categories of anti-tumour agents :-

25 (i) antiproliferative/antineoplastic drugs and combinations thereof, as used in medical oncology, such as alkylating agents (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside and hydroxyurea; antitumour antibiotics (for example
30 anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like taxol and

- 23 -

taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecin);

- (ii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droloxifene and idoxifene), oestrogen receptor down regulators (for example
5 fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestogens (for example megestrol acetate), aromatase inhibitors (for example as anastrozole, letrozole, vorazole and exemestane) and inhibitors of 5 α -reductase such as finasteride;
- 10 (iii) Agents which inhibit cancer cell invasion (for example metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function);
- (iv) inhibitors of growth factor function, for example such inhibitors include growth factor antibodies, growth factor receptor antibodies (for example the anti-erbb2 antibody trastuzumab [Herceptin™] and the anti-erbb1 antibody cetuximab [C225]) , farnesyl
15 transferase inhibitors, MEK inhibitors, tyrosine kinase inhibitors and serine/threonine kinase inhibitors, for example inhibitors of the epidermal growth factor family (for example EGFR family tyrosine kinase inhibitors such as *N*-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, AZD1839), *N*-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-acrylamido-*N*-(3-chloro-
20 4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), for example inhibitors of the platelet-derived growth factor family and for example inhibitors of the hepatocyte growth factor family;
- (v) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cell growth factor antibody
25 bevacizumab [Avastin™], compounds such as those disclosed in International Patent Applications WO 97/22596, WO 97/30035, WO 97/32856 and WO 98/13354) and compounds that work by other mechanisms (for example linomide, inhibitors of integrin α v β 3 function and angiostatin);
- (vi) vascular damaging agents such as Combretastatin A4 and compounds disclosed in
30 International Patent Applications WO 99/02166, WO00/40529, WO 00/41669, WO01/92224, WO02/04434 and WO02/08213;
- (vii) antisense therapies, for example those which are directed to the targets listed above, such as ISIS 2503, an anti-ras antisense;

- (viii) gene therapy approaches, including for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCA1 or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or
- 5 radiotherapy such as multi-drug resistance gene therapy;
- (ix) immunotherapy approaches, including for example ex-vivo and in-vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as
- 10 cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies;
- (x) cell cycle inhibitors including for example CDK inhibitors (eg flavopiridol) and other inhibitors of cell cycle checkpoints (eg checkpoint kinase); inhibitors of aurora kinase and other kinases involved in mitosis and cytokinesis regulation (eg mitotic kinesins); and histone
- 15 deacetylase inhibitors; and
- (xi) endothelin antagonists, including endothelin A antagonists, endothelin B antagonists and endothelin A and B antagonists; for example ZD4054 and ZD1611 (WO 96 40681), atrasentan and YM598.

Such conjoint treatment may be achieved by way of the simultaneous, sequential or

20 separate dosing of the individual components of the treatment. Such combination products employ the compounds of this invention within the dosage range described hereinbefore and the other pharmaceutically-active agent within its approved dosage range.

In addition to their use in therapeutic medicine, the compounds of formula (I) and their pharmaceutically acceptable salts are also useful as pharmacological tools in the

25 development and standardisation of in vitro and *in vivo* test systems for the evaluation of the effects of inhibitors of B-Raf in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.

In the above other pharmaceutical composition, process, method, use and medicament manufacture features, the alternative and preferred embodiments of the compounds of the

30 invention described herein also apply.

Examples

The invention will now be illustrated by the following non limiting examples in which, unless stated otherwise:

- 25 -

- (i) temperatures are given in degrees Celsius ($^{\circ}\text{C}$); operations were carried out at room or ambient temperature, that is, at a temperature in the range of 18-25 $^{\circ}\text{C}$;
- (ii) organic solutions were dried over anhydrous sodium sulphate; evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 Pascals;
- 5 4.5-30mmHg) with a bath temperature of up to 60 $^{\circ}\text{C}$;
- (iii) in general, the course of reactions was followed by TLC and reaction times are given for illustration only;
- (iv) final products had satisfactory proton nuclear magnetic resonance (NMR) spectra and/or mass spectral data;
- 10 (v) yields are given for illustration only and are not necessarily those which can be obtained by diligent process development; preparations were repeated if more material was required;
- (vii) when given, NMR data is in the form of delta values for major diagnostic protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as an internal standard, determined at 400 MHz using perdeuterio dimethyl sulphoxide (DMSO- d_6) as solvent unless
- 15 otherwise indicated;
- (vii) chemical symbols have their usual meanings; SI units and symbols are used;
- (viii) solvent ratios are given in volume:volume (v/v) terms; and
- (ix) mass spectra were run with an electron energy of 70 electron volts in the chemical ionization (CI) mode using a direct exposure probe; where indicated ionization was effected
- 20 by electron impact (EI), fast atom bombardment (FAB) or electrospray (ESP); values for m/z are given; generally, only ions which indicate the parent mass are reported; and unless otherwise stated, the mass ion quoted is $(\text{MH})^+$;
- (x) where a synthesis is described as being analogous to that described in a previous example the amounts used are the millimolar ratio equivalents to those used in the previous example;
- 25 (xi) the following abbreviations have been used:
- | | |
|--------|---------------------------------------|
| THF | tetrahydrofuran; |
| DMF | <i>N,N</i> -dimethylformamide; |
| DCM | dichloromethane; |
| DIC | <i>N,N'</i> -diisopropylcarbodiimide; |
| 30 DCE | dichloroethane; |
| DIEA | diisopropylethylamine; |
| TEA | triethylamine; |
| DPPA | diphenylphosphorylazide; |

- 26 -

BINAP (+/-)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl;
 Pd₂dba₃ tris(dibenzylideneacetone)dipalladium (0);
 DMF *N,N*-dimethylformamide; and
 EtOAc ethyl acetate; and

- 5 (xii) "ISCO" refers to normal phase flash column chromatography using 12g and 40g pre-packed silica gel cartridges used according to the manufacturers instruction obtained from ISCO, Inc, 4700 superior street Lincoln, NE, USA;
- (xiii) "Reverse phase Gilson" refers to a YMC-AQC18 reverse phase HPLC Column with dimension 20mm/100 and 50mm/250 in water/acetonitrile with 0.1% TFA as mobile phase,
 10 obtained from Waters Corporation 34, Maple street, Milford MA, USA.

Example 1

N-[4-Chloro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea

- 15 A solution of 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene (84 mg, 0.378 mmol) in THF (2 ml) was treated with 6-(4-aminophenoxy)-3-methylquinazolin-4(3*H*)-one (Method 9; 101 mg, 0.378 mmol). The reaction mixture was stirred for 12 h at 25 °C. The resulting white precipitate was collected by vacuum filtration and then purified by column chromatography utilizing an ISCO system (EtOAc-MeOH) giving the desired product (144
 20 mg, 78%) of the desired product. NMR: 9.18 (s, 1 H), 8.92 (s, 1 H), 8.30 (s, 1 H), 8.11 (d, 1 H), 7.71 (d, 1 H), 7.62 (m, 2 H), 7.54 (m, 3 H), 7.41 (d, 1 H), 7.09 (d, 2 H), 3.46 (s, 3 H); *m/z* 489.

Examples 2-11

- 25 The following compounds were prepared by the procedure of Example 1, using the indicated starting materials.

Ex	Compound	NMR	<i>m/z</i>	SM
2	<i>N</i> -[4-Fluoro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	9.07 (s, 1 H), 8.90 (s, 1 H), 8.30 (s, 1 H), 8.00 (d, 1 H), 7.71 (d, 1 H), 7.64 (m, 1 H), 7.53 (m, 3 H), 7.44 (d, 1 H), 7.41 (d, 1 H), 7.09 (d, 2 H), 3.46 (s, 3 H)	473	Method 9 and 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene

Ex	Compound	NMR	m/z	SM
3	<i>N</i> -[4-Chloro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{3-methyl-4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	9.19 (s, 1 H), 8.87 (s, 1 H), 8.30 (s, 1 H), 8.14 (d, 1 H), 7.72 (d, 1 H), 7.60 - 7.67 (m, 2 H), 7.48 - 7.56 (m, 2 H), 7.37 (dd, 1 H), 7.25 (d, 1 H), 7.03 (d, 1 H), 3.46 (s, 3 H), 2.12 (s, 3 H)	502	Method 10 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene
4	tert-Butyl {3-[6-{4-[(4-chloro-3-(trifluoromethyl)phenyl)amino]carbonyl)amino]phenoxy}-4-oxoquinazolin-3(4 <i>H</i>)-yl]propyl}carbamate		633	Method 15 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene
5	<i>N</i> -{4-[(3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}- <i>N'</i> -[3-(trifluoromethyl)phenyl]urea	9.06 (s, 1 H), 8.87 (s, 1 H), 8.29 (s, 1 H), 8.01 (s, 1 H), 7.70 (d, 1 H), 7.48 - 7.60 (m, 5 H), 7.41 (s, 1 H), 7.30 (d, 1 H), 7.09 (d, 2 H), 3.46 (s, 3 H)	455	Method 9 and 1-isocyanato-3-(trifluoromethyl)benzene
6	<i>N</i> -[3-Fluoro-5-(trifluoromethyl)phenyl]- <i>N'</i> -{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	9.27 (s, 1 H), 8.99 (s, 1 H), 8.30 (s, 1 H), 7.68 - 7.73 (m, 2 H), 7.61 (d, 1 H), 7.51 - 7.57 (m, 3 H), 7.41 (d, 1 H), 7.22 (d, 1 H), 7.10 (d, 2 H), 3.46 (s, 3 H)	473	Method 9 and 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene
7	<i>N</i> -[2-Fluoro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	9.25 (s, 1 H), 8.90 (s, 1 H), 8.62 (d, 1 H), 8.29 (s, 1 H), 7.70 (d, 1 H), 7.45 - 7.57 (m, 4 H), 7.35 - 7.42 (m, 2 H), 7.10 (d, 2 H), 3.45 (s, 3 H)	473	Method 9 and 2-fluoro-1-isocyanato-3-(trifluoromethyl)benzene

Ex	Compound	NMR	m/z	SM
8	<i>N</i> -[4-Chloro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{2-methyl-4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	9.45 (s, 1 H), 8.30 (s, 1 H), 8.11 (d, 2 H), 7.73 (dd, 2 H), 7.58 - 7.65 (m, 2 H), 7.54 (dd, 1 H), 7.42 (d, 1 H), 7.02 (s, 1 H), 6.95 (dd, 1 H), 3.46 (s, 3 H), 2.24 (s, 3 H)	503	Method 13 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene
9	<i>N</i> -[4-Chloro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{4-[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	12.24 (s, 1 H), 9.18 (s, 1 H), 8.92 (s, 1 H), 8.11 (d, 1 H), 8.02 (s, 1 H), 7.70 (d, 1 H), 7.58 - 7.66 (m, 2 H), 7.51 - 7.58 (m, 3 H), 7.36 (d, 1 H), 7.10 (d, 2 H)	476	Method 12 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene
10	<i>N</i> -[4-Chloro-3-(trifluoromethyl)phenyl]- <i>N'</i> -{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}urea	9.26 (s, 1 H), 8.85 (s, 1 H), 8.47 (s, 1 H), 8.09 - 8.20 (m, 2 H), 7.60 - 7.66 (m, 3 H), 7.54 (d, 1 H), 7.42 (dt, 3 H), 7.13 (d, 2 H), 3.47 (s, 3 H)	489	Method 14 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene
11	<i>N</i> -[4-Chloro-3-(trifluoromethyl)phenyl]- <i>N'</i> -[4-({3-[(1-methylpiperidin-3-yl)methyl]-4-oxo-3,4-dihydroquinazolin-6-yl}oxy)phenyl]urea	9.83 (s, 1 H), 9.75 (s, 1 H), 9.39 (s, 1 H), 8.32 (s, 1 H), 8.11 (s, 1 H), 7.73 (d, 1 H), 7.52 - 7.63 (m, 4 H), 7.41 (d, 1 H), 7.09 (d, 2 H), 3.83 - 3.96 (m, 1 H), 3.28 - 3.34 (m, 2 H), 2.67 - 2.82 (m, 5 H), 2.31 (m, 1 H), 1.71-1.84 (m, 2 H), 1.23 - 1.27 (m, 2 H), 0.85 (m, 1 H)	587	Method 16 and 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene

Example 12

3-[6-{4-[(4-Chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-4-oxoquinazolin-3(4*H*)-yl]propan-1-aminium chloride

- 5 A solution of *tert*-butyl {3-[6-{4-[(4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-4-oxoquinazolin-3(4*H*)-yl]propyl} carbamate (Example 4; 0.053 g,

0.084 mmol) in 4 N HCl in 1,4-dioxane (2 ml) was stirred at 25 °C for 45 min. The reaction mixture was concentrated under reduced pressure to give the desired product. NMR: 9.62 (s, 1 H), 9.28 (s, 1 H), 8.36 (s, 1 H), 8.11 (d, 1 H), 7.73 (d, 3 H), 7.51 - 7.62 (m, 5 H), 7.40 (d, 1 H), 7.09 (d, 2 H), 4.02 (t, 2 H), 2.78 (m, 2 H), 1.92 - 2.02 (m, 2 H); *m/z* 569.

5

Example 13

N-[3-(1-Cyano-1-methylethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea

A solution of 2-(3-aminophenyl)-2-methylpropanenitrile (Method 22, 40 mg, 0.250 mmol) and TEA (174 µl, 1.250 mmol) in DCM (5 ml) was treated with DIC (50 mg, 0.308 mmol). After 15 minutes of stirring, the solvent was removed under reduced pressure to give the desired intermediate. The resulting solid was dissolved in THF (5 ml) and 6-(4-aminophenoxy)-3-methylquinazolin-4(3*H*)-one (Method 9, 0.066 g, 0.250 mmol) was then added. After completion of the reaction, the solvent was removed under reduced pressure and the crude material was purified by reverse phase Gilson to provide the desired product (43 mg, 38 %). NMR: 8.92 (s, 1 H), 8.83 (s, 1 H), 8.32 (s, 1 H), 7.71 (d, 1 H), 7.67 (s, 1 H), 7.57 - 7.51 (m, 3 H), 7.44 - 7.40 (m, 2 H), 7.33 (t, 1 H), 7.12 - 7.07 (m, 3 H), 3.47 (s, 3 H), 1.68 (s, 6 H); *m/z* 453.

20 **Example 14**

The following compound was prepared by the procedure of Example 13, using the indicated starting materials.

Ex	Compound	NMR	<i>m/z</i>	SM
14	<i>N</i> -[4-(1-Cyano-1-methylethyl)phenyl]- <i>N'</i> -{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea	8.81 (d, 2 H), 8.30 (s, 1 H), 7.70 (d, 1 H), 7.55 - 7.47 (m, 5 H), 7.43 - 7.39 (m, 3 H), 7.09 (d, 2 H), 3.46 (s, 3 H), 1.65 (s, 6 H)	454	Method 23 and Method 9

Example 15*N*-[3-(1,1-Difluoroethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea

A solution of [3-(1,1-difluoroethyl)phenyl]amine (Method 25, 70 mg, 0.45 mmol) and TEA (322 μ L, 2.22 mmol) in DCE (4 ml) was treated with triphosgene (132 mg, 0.445 mmol). The reaction mixture was stirred at \sim 25 $^{\circ}$ C for 30 min and then at 70 $^{\circ}$ C for 90 min. The solvent was removed under reduced pressure to give the desired intermediate. The resulting solid was dissolved in THF (5 ml) and 6-(4-aminophenoxy)-3-methylquinazolin-4(3*H*)-one (Method 9, 100 mg, 0.401 mmol) was added. The reaction mixture stirred for 2 hr. The solvent was removed under reduced pressure and the residue was redissolved in EtOAc. The organics were dried by NaCl(sat) then Na₂SO₄(s) and the solvents were again removed under reduced pressure. The crude material was purified by reverse phase Gilson to yield 84 mg (42 %) of a white solid. NMR: 9.16 (s, 1 H), 9.07 (s, 1 H), 8.40 (s, 1 H), 7.77 – 7.69 (m, 2 H), 7.58 – 7.45 (m, 4 H), 7.43 – 7.34 (m, 2 H), 7.17 – 7.05 (m, 3 H), 3.47 (s, 3 H), 1.94 (t, 3 H); *m/z* 450.

Example 16

The following compound was prepared by the procedure of Example 15, using the indicated starting materials.

Ex	Compound	NMR	<i>m/z</i>	SM
16	<i>N</i> -{4-[(3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}- <i>N'</i> -[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]urea	9.75 (s, 1 H), 9.62 (s, 1 H), 8.35 (s, 1 H), 8.04 (s, 1 H), 7.67 - 7.81 (m, 2 H), 7.50 - 7.62 (m, 4 H), 7.39 (s, 1 H), 7.10 (d, 2 H), 3.65 (s, 8 H), 3.46 (s, 3 H), 2.78 (s, 3 H)	566	Method 28 and Method 9

20

Example 17*N*-{4-[(3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-*N'*-[6-(trifluoromethyl)pyrimidin-4-yl]urea

A the solution of 2,2,2-trichloro-*N*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}acetamide (Method 29, 206 mg, 0.50 mmol) and NaOH (52 mg, 1.3 mmol) in

25

DMSO (3 ml) was treated with 6-(trifluoromethyl)pyrimidin-4-amine (Method 30, 98 mg, 0.60 mmol). The reaction mixture was stirred at 80 °C until the starting material was consumed. The reaction mixture was cooled to ~25 °C and then added to water. The aqueous layer was extracted with DCM and the combined extracts were washed with NH₄Cl(aq). The organic solution was dried over Na₂SO₄(s) and the solvents were removed under reduced pressure. The crude material was purified by crystallization to yield 80 mg of desired compound (35 %). NMR: 10.23 (s, 1 H), 9.67 (s, 1 H), 9.00 (s, 1 H), 8.31 (s, 1 H), 8.19 (s, 1 H), 7.71 (d, 1 H), 7.63 – 7.51 (m, 3 H), 7.46 – 7.39 (m, 1 H), 7.19 – 7.10 (m, 2 H), 3.46 (s, 3 H); *m/z* 456.

10

Example 18

The following compound was prepared by the procedure of Example 17, using the indicated starting materials.

Ex	Compound	NMR	<i>m/z</i>	SM
18	<i>N</i> -{4-[(3-Methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}- <i>N'</i> -[2-(trifluoromethyl)pyridin-4-yl]urea	9.63 (s, 1 H), 9.18 (s, 1 H), 8.53 (d, 1 H), 8.31 (s, 1 H), 8.06 (s, 1 H), 7.71 (d, 1 H), 7.62 – 7.51 (m, 4 H), 7.41 (s, 1 H), 7.15 – 7.08 (m, 2 H), 3.46 (s, 3 H)	455	Method 29 and Method 21

15 **Preparation of starting materials****Method 1**6-Hydroxy-3-methylquinazolin-4(3*H*)-one

2-Amino-5-hydroxybenzoic acid (2.00 g, 0.0131 mol) was reacted with *N*-methylformamide (5 ml) at 180 °C for 4 hours. The reaction was quenched with H₂O and the resulting precipitate was collected by vacuum filtration to give 1.84 g (80%) of a brown solid; *m/z* 177.

Methods 2-3

25 The following compounds were prepared by the procedure of Method 1, using the indicated starting materials.

Method	Compound	m/z	SM
2	6-Hydroxyquinazolin-4(3H)-one	163	formamide and 2-amino-5-hydroxybenzoic acid
3	3-Methyl-6-nitroquinazolin-4(3H)-one	206	N-methylformamide and 2-amino-5-nitrobenzoic acid

Method 43-Methyl-6-(4-nitrophenoxy)quinazolin-4(3H)-one

6-Hydroxy-3-methylquinazolin-4(3H)-one (Method 1, 1.00 g, 5.68 mol) and K₂CO₃ (2.35 g, 17.04 mmol, 3.0 equiv) in DMF (20 ml) were reacted with 1-fluoro-4-nitrobenzene (602 μ L, 5.68 mmol) at 100 °C under Ar. The reaction mixture stirred for 12 h and then quenched with H₂O. The resulting yellow precipitate was collected by vacuum filtration to give 1.69 g of the desired product (99%); *m/z* 298.

10 **Method 5-8**

The following compounds were prepared by the procedure of Method 4, using the indicated starting materials.

Method	Compound	m/z	SM
5	3-Methyl-6-[(2-methyl-4-nitrophenyl)oxy]quinazolin-4(3H)-one	312	Method 1 and 1-fluoro-2-methyl-4-nitrobenzene
6	6-(4-Nitrophenoxy)quinazolin-4(3H)-one	284	Method 2 and 1-fluoro-4-nitrobenzene
7	3-Methyl-6-(3-methyl-4-nitrophenoxy)quinazolin-4(3H)-one	312	Method 1 and 4-fluoro-2-methyl-1-nitrobenzene
8	3-Methyl-6-[(4-nitrophenyl)amino]quinazolin-4(3H)-one	297	Method 11 and 1-fluoro-4-nitrobenzene

Method 915 6-(4-Aminophenoxy)-3-methylquinazolin-4(3H)-one

3-Methyl-6-(4-nitrophenoxy)quinazolin-4(3H)-one (Method 4, 1.00 g, 3.74 mmol) was dissolved in MeOH (25 ml). Pd on carbon (30%) (100 mg) was then added. The reaction mixture was then treated with a hydrogen atmosphere for 12 h. The reaction mixture was then

filtered through diatomaceous earth and the solvents were removed under reduced pressure to give a brown solid (898 mg, 99%); *m/z* 268.

Method 10-16

- 5 The following compounds were prepared by the procedure of Method 9, using the indicated starting materials.

Method	Compound	<i>m/z</i>	SM
10	6-[(4-Amino-2-methylphenyl)oxy]-3-methylquinazolin-4(3 <i>H</i>)-one	282	Method 5
11	6-Amino-3-methylquinazolin-4(3 <i>H</i>)-one	176	Method 3
12	6-(4-Aminophenoxy)quinazolin-4(3 <i>H</i>)-one	254	Method 6
13	6-(4-Amino-3-methylphenoxy)-3-methylquinazolin-4(3 <i>H</i>)-one	282	Method 7
14	6-[(4-Aminophenyl)amino]-3-methylquinazolin-4(3 <i>H</i>)-one	267	Method 8
15	<i>tert</i> -Butyl {3-[6-(4-aminophenoxy)-4-oxoquinazolin-3(4 <i>H</i>)-yl]propyl} carbamate	411	Method 17
16	6-(4-Aminophenoxy)-3-[(1-methylpiperidin-3-yl)methyl]quinazolin-4(3 <i>H</i>)-one	365	Method 18

Method 17

tert-Butyl {3-[6-(4-nitrophenoxy)-4-oxoquinazolin-3(4*H*)-yl]propyl} carbamate

- 10 A solution of 6-(4-nitrophenoxy)quinazolin-4(3*H*)-one (Method 6, 500 mg, 1.77 mmol) and K₂CO₃ (734 mg, 5.31 mmol, 3.0 equiv) in DMF (3 ml) was reacted with *tert*-butyl (3-iodopropyl)carbamate (Method 19, 503 mg, 1.77 mmol) at 70 °C for 12 h. The reaction was quenched with H₂O and extracted with EtOAc. The organics were dried by NaCl(sat) then Na₂SO₄(s) The solvents were removed under reduced pressure. The residue was then
- 15 purified by column chromatography utilizing an ISCO system (EtOAc-hexanes) to give 250 mg (32%) of the desired product; *m/z* 441.

Method 18

- The following compound was prepared by the procedure of Method 17, using the
- 20 indicated starting materials.

Method	Compound	m/z	SM
18	3-[(1-Methylpiperidin-3-yl)methyl]-6-(4-nitrophenoxy)quinazolin-4(3H)-one	395	Method 6 and 3-chloromethyl-1-methylpiperidine hydrochloride

Method 19*tert*-Butyl (3-iodopropyl)carbamate

Triphenylphosphine (11.21 g, 42.8 mmol) and imidazole (2.91 g, 42.8 mmol, 1.5 equiv) in DCM at 0 °C under Ar was treated with I₂ (5.43 g, 30 mmol, 0.8 equiv). After 5 min, *tert*-butyl (3-hydroxypropyl)carbamate (4.88 ml, 28.5 mmol) in DCM was added. The reaction was stirred for 1 h and then quenched with 10% HCl. The reaction mixture was extracted with EtOAc and the organic layer was washed with NaHCO₃(sat). The organics were dried with NaCl(sat) and Na₂SO₄(s) and then removed under reduced pressure. The residue was then purified by column chromatography utilizing an ISCO system (EtOAc-hexanes, 0.1% TEA) to give 4.54 g (76%) of a white solid; *m/z* 286.

Method 202-(Trifluoromethyl)pyridine 1-oxide

A solution of 2-(trifluoromethyl)pyridine (5.02 g, 34.0 mmol) in DCM (100 ml) was treated with *meta*-chloroperoxybenzoic acid (15.2 g, 68.0 mmol). The reaction was stirred at ~25 °C for ~12 h. The reaction mixture was quenched with NaHCO₃(aq). The organics were dried with NaCl(sat) and Na₂SO₄(s) and then removed under reduced pressure. The residue was purified by silica gel chromatography to provide 420 mg (38 %) of the desired product. NMR: 7.92 - 7.85 (m, 2 H), 7.69 (d, 1 H), 7.52 (t, 1 H).

Method 212-(Trifluoromethyl)pyridin-4-amine

A solution of 2-(trifluoromethyl)pyridine 1-oxide (Method 20, 3.3 g, 20.0 mmol) in H₂SO₄ (15 ml) was treated with a solution of nitric fuming acid (20 ml) and H₂SO₄ (10 ml) at 0 °C. The reaction mixture was stirred for 4 h at 125 °C. The reaction mixture was then added to ice. The pH of the aqueous solution was adjusted to 7 by the addition of NaOH (4.0 M) and then extracted with DCM. The combined extracts were removed under reduced pressure to provide the desired product. A solution of 4-nitro-2-(trifluoromethyl)pyridine 1-oxide (50 mg,

0.24 mmol) and 10% Pd/C (5 mg) in MeOH (10 ml) were treated with a H₂ atmosphere for ~12 h. The reaction mixture was filtered and the solvent was removed under reduced pressure to yield 20 mg (9 % over two steps). NMR: 8.32 (d, 1 H), 6.90 (s, 1 H), 6.65 (d, 1 H), 4.42 (s, 2 H).

5

Method 22

2-(3-Aminophenyl)-2-methylpropanenitrile

A solution of 3-(1-cyano-1-methylethyl)benzoic acid (250 mg, 1.3 mmol) and DIEA (476 µl, 2.6 mmol) was added DPPA (572 µl, 2.6 mmol) in *t*-BuOH. The reaction mixture
10 was stirred at 100 °C for ~12 h. The solvents were then removed under reduced pressure. The residue was then purified by column chromatography utilizing an ISCO system (EtOAc-hexanes) to yield a clear oil which was used directly in the next step. The material was dissolved in a neat solution of 1.0 M HCl in 1, 4-dioxane (10 ml). The reaction mixture was allowed to stir over three days. Afterwards, the solvent was removed under reduced pressure
15 and redissolved in DCM. The resulting precipitate was collected by vacuum filtration (100 mg, 47 % over two steps). NMR (300 MHz): 7.69 – 7.55 (m, 3 H), 7.37 (d, 1 H), 1.74 (s, 6 H).

Method 23

20 2-(4-Aminophenyl)-2-methylpropanenitrile

A solution of BINAP (4.1 mg, 0.0067 mmol), Pd₂dba₃ (2.0 mg, 0.0022 mmol), sodium *t*-butoxide (120 mg, 1.25 mmol), benzophenone imine (180 µl, 1.01 mmol), and 2-(4-bromophenyl)-2-methylpropanenitrile was stirred for ~12 h at 80 °C. The reaction mixture was diluted with Et₂O and filtered. The solvents were removed under reduced pressure, and
25 the resulting solid was dissolved in THF (10 ml). 10% HCl was added and the reaction mixture was allowed to stir for 1 h. The organic layer was removed from the aqueous layer and the pH of the aqueous layer was adjusted to ~8 by the addition of 10% NaOH. The solution was extracted with DCM and the combined extracts were dried over Na₂SO₄(s). The solvents were removed under reduced pressure. The residue was then purified by column
30 chromatography utilizing an ISCO system (EtOAc-hexanes) to give 123 mg (86%) of an orange oil; *m/z* 160.

Method 241-(1,1-Difluoroethyl)-3-nitrobenzene

A solution of 1-(3-nitrophenyl)ethanone (2.0 g, 12.1 mmol) in DeoxoFluor™ (15 ml) was stirred for ~12 h at 80 °C. The reaction mixture was diluted in EtOAc and added to
5 NaHCO₃(sat). The aqueous layer was further extracted with EtOAc. The organics were dried with NaCl(sat) and Na₂SO₄(s) and then removed under reduced pressure. The residue was then purified by column chromatography utilizing an ISCO system (EtOAc-hexanes) to give 1.2 g (55 %) of a colourless oil. NMR: 8.42 (s, 1 H), 8.33 (d, 1 H), 7.89 (d, 1 H), 7.72 – 7.63 (m, 1 H), 2.00 (t, 3 H).

10

Method 25[3-(1,1-Difluoroethyl)phenyl]amine

A solution of 1-(1,1-difluoroethyl)-3-nitrobenzene (Method 24, 1.2 g, 6.42 mmol) and Pd/C (10 %) (120 mg) in MeOH was treated with a H₂ atmosphere. The reaction mixture was
15 stirred for 3 h and then filtered through diatomaceous earth. The solvent was removed under reduced pressure to provide an orange oil (958 mg, 95%); *m/z* 158.

Method 26[3-Nitro-5-(trifluoromethyl)phenyl]methanol

A solution of 3-nitro-5-(trifluoromethyl)benzoic acid (5.0 g, 21.2 mmol) in THF (100 ml) was treated with 2.0 M BH₃Me₂S (15.9 ml, 31.9 mmol) at 0 °C. The reaction was refluxed for ~12 h. The mixture was quenched with glacial acetic acid-H₂O (2:1). EtOAc and 30% K₂CO₃ were added to the reaction mixture. The separated organics were dried with NaCl(sat) and Na₂SO₄(s) and then removed under reduced pressure to give 4.9 g (99%) of a
25 yellow oil. NMR: 8.41 (s, 1 H), 8.37 (s, 1 H), 7.98 (s, 1 H), 4.91 (s, 2 H).

Method 271-Methyl-4-[3-nitro-5-(trifluoromethyl)benzyl]piperazine

A solution of [3-nitro-5-(trifluoromethyl)phenyl]methanol (Method 26, 843 mg, 3.81
30 mmol) and TEA (1.6 ml, 11.4 mmol) in DCM (10 ml) was treated with methanesulfonyl chloride (295 μL, 3.81 mmol). The reaction stirred for 10 min at 25 °C. The solvent was removed under reduced pressure and the intermediate was redissolved in DCM (10 ml). TEA (1.6 ml, 11.4 mmol) and *N*-methylpiperazine (466 μL, 4.19 mmol) were then added. The

reaction mixture was stirred for ~12 h at ~25 °C. The solvent was removed under reduced pressure and the crude material was used directly; *m/z* 303.

Method 28

5 [3-[(4-Methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]amine

A solution of 1-methyl-4-[3-nitro-5-(trifluoromethyl)benzyl]piperazine (Method 27, 1.2 g, 6.42 mmol) and Pd/C (10 %) (120 mg) in MeOH was treated with a H₂ atmosphere. After 3 h, the mixture was filtered through diatomaceous earth and the solvents were removed under reduced pressure to give the desired material; *m/z* 274.

10

Method 29

2,2,2-Trichloro-N-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}acetamide

Phosphorus trichloride, 6-(4-aminophenoxy)-3-methylquinazolin-4(3*H*)-one and trichloroacetic acid were mixed under refluxing conditions. Afterwards, the reaction mixture
15 was quenched with ice water and solids were collected for the next step.


Method 30

6-(Trifluoromethyl)pyrimidin-4-amine

Phenylphosphonic dichloride (28.75 ml, 0.18 mol) and 6-(trifluoromethyl)-4-
20 pyrimidinol (25.0 g, 0.15 mol) were heated at 130 °C under N₂ for ~30min. The reaction mixture was cooled to ~25 °C. Distillation of the reaction mixture yielded 22.0 g of a colourless oil. The 4-chloro-6-(trifluoromethyl)pyrimidine (22.0 g, 0.12 mol) was then treated with a solution of NH₃/CH₃OH (100 ml). The reaction mixture was stirred at ~25 °C for 12 h. The solvents were removed under reduced pressure and the crude material was purified by
25 silica gel chromatography to provide 9.18 g (29 % over two steps) of the desired product; *m/z* 163.

Claims

1. A compound of formula (I):



- 5 (I)

wherein:

Ring A is carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R⁷;


- R¹ is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, *N*-(C₁₋₆alkoxy)sulphamoyl, *N*-(C₁₋₆alkyl)-*N*-(C₁₋₆alkoxy)sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R⁸- or heterocyclyl-R⁹-; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹¹;

n is selected from 0-4; wherein the values of R¹ may be the same or different;

- R² is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₁₋₆alkoxy, C₁₋₆alkanoyl, C₁₋₆alkanoyloxy, *N*-(C₁₋₆alkyl)amino, *N,N*-(C₁₋₆alkyl)₂amino, C₁₋₆alkanoylamino, *N*-(C₁₋₆alkyl)carbamoyl, *N,N*-(C₁₋₆alkyl)₂carbamoyl, C₁₋₆alkylS(O)_a wherein a is 0 to 2, C₁₋₆alkoxycarbonyl, *N*-(C₁₋₆alkyl)sulphamoyl, *N,N*-(C₁₋₆alkyl)₂sulphamoyl, C₁₋₆alkylsulphonylamino, carbocyclyl-R¹²- or heterocyclyl-R¹³-; wherein R² may be optionally substituted on carbon by one or more R¹⁴; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R¹⁵;

q is 0-2; wherein the values of R² may be the same or different;

X is NR¹⁶ or O;

- R^3 and R^6 are independently selected from hydrogen, halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a 5 wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{17} - or heterocyclyl- R^{18} -; wherein R^3 and R^6 independently of each other may be optionally substituted on carbon by one or more R^{19} ; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{20} ;
- 10 R^4 , R^5 and R^{16} are independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} alkanoyl, C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, carbocyclyl, heterocyclyl, N -(C_{1-6} alkyl)carbamoyl and N,N -(C_{1-6} alkyl)carbamoyl; wherein R^4 , R^5 and R^{16} independently of each other may be optionally substituted on carbon by one or more R^{21} ;
- m is 3; wherein the values of R^6 may be the same or different;
- 15 the bond “” between the -NR⁵- and -CR³- of formula (I) is either (i) a single bond wherein R^5 is as defined above, or (ii) a double bond wherein R^5 is absent;
- R^{10} , R^{14} , R^{19} and R^{21} are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkanoyloxy, N -(C_{1-6} alkyl)amino, N,N -(C_{1-6} alkyl)₂amino, 20 C_{1-6} alkanoylamino, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)₂carbamoyl, C_{1-6} alkylS(O)_a wherein a is 0 to 2, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxycarbonylamino, N -(C_{1-6} alkyl)sulphamoyl, N,N -(C_{1-6} alkyl)₂sulphamoyl, C_{1-6} alkylsulphonylamino, carbocyclyl- R^{22} - or heterocyclyl- R^{23} -; wherein R^{10} , R^{14} , R^{19} and R^{21} independently of each other may be optionally substituted on carbon by one or more R^{24} ; and wherein if said heterocyclyl contains an -NH- moiety that 25 nitrogen may be optionally substituted by a group selected from R^{25} ;
- R^8 , R^9 , R^{12} , R^{13} , R^{17} , R^{18} , R^{22} and R^{23} are independently selected from a direct bond, -O-, -N(R^{26})-, -C(O)-, -N(R^{27})C(O)-, -C(O)N(R^{28})-, -S(O)_s-, -SO₂N(R^{29})- or -N(R^{30})SO₂-; wherein R^{26} , R^{27} , R^{28} , R^{29} and R^{30} is hydrogen, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl and s is 0-2;
- R^7 , R^{11} , R^{15} , R^{20} and R^{25} are independently selected from C_{1-6} alkyl, C_{1-6} alkanoyl, 30 C_{1-6} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carbamoyl, N -(C_{1-6} alkyl)carbamoyl, N,N -(C_{1-6} alkyl)carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;
- R^{24} is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl,

- 40 -

- acetoxo, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl,
- 5 *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;
or a pharmaceutically acceptable salt thereof.
2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed
10 in claim 1 wherein Ring A is phenyl, pyrimidinyl or pyridyl.
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in either claim 1 or claim 2 wherein R¹ is a substituent on carbon and is selected from halo or C₁₋₆alkyl; wherein R¹ may be optionally substituted on carbon by one or more R¹⁰; wherein
15 R¹⁰ is halo, cyano or heterocyclyl-R²³-; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R²⁵;
R²³ is a direct bond; and
R²⁵ is C₁₋₆alkyl.
- 20 4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-3 wherein n is 1 or 2; wherein the values of R¹ may be the same or different.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed
25 in any one of claims 1-4 wherein R² is C₁₋₆alkyl.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-5 wherein q is 0 or 1.
- 30 7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-6 wherein X is NR¹⁶ or O; wherein R¹⁶ is hydrogen.

- 41 -


8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-7 wherein R^3 and R^6 are hydrogen.

9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-8 wherein R^4 is selected from hydrogen and C_{1-6} alkyl; wherein R^4 may be optionally substituted on carbon by one or more R^{21} ;


R^{21} is selected from amino, C_{1-6} alkoxycarbonylamino or heterocyclyl- R^{23} -; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R^{25} ;

10 R^{23} is a direct bond; and

R^{25} is C_{1-6} alkyl.

10. A compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-9 wherein the bond “” between the -NR⁵- and -CR³- of formula (I) is a double bond wherein R^5 is absent.

11. A compound of formula (I):



(I)

20 wherein:

Ring A is phenyl, pyrimidin-4-yl or pyrid-4-yl;

R^1 is a substituent on carbon and is selected from fluoro, chloro, trifluoromethyl, 1,1-difluoroethyl, 1-methylpiperazin-4-ylmethyl or 1-methyl-1-cyanoethyl;

n is 1 or 2; wherein the values of R^1 may be the same or different;

25 R^2 is methyl;

q is 0 or 1;


X is NH or O;

R^3 and R^6 are hydrogen;

m is 3; wherein the values of R^6 may be the same or different;


- 42 -

R^4 is methyl, 3-aminopropyl, 1-methylpiperidin-3-ylmethyl or 3-(*t*-butoxycarbonylamino)propyl;

the bond “” between the $-NR^5-$ and $-CR^3-$ of formula (I) is a double bond wherein R^5 is absent;

5 or a pharmaceutically acceptable salt thereof.

12. A compound of formula (I):



(I)

10 selected from:

N-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

N-[4-fluoro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

15 *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{3-methyl-4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

tert-butyl {3-[6-{4-[[{4-chloro-3-(trifluoromethyl)phenyl]amino} carbonyl]amino]phenoxy}-4-oxoquinazolin-3(4*H*)-yl]propyl} carbamate;

N-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-*N'*-[3-

20 (trifluoromethyl)phenyl] urea;

N-[3-fluoro-5-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

N-[2-fluoro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

25 *N*-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{2-methyl-4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl} urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino]phenyl}urea;

N-[4-chloro-3-(trifluoromethyl)phenyl]-*N'*-[4-({3-[(1-methylpiperidin-3-yl)methyl]-4-oxo-3,4-dihydroquinazolin-6-yl}oxy)phenyl]urea;

5 *N*-(4-{[3-(3-aminopropyl)-4-oxo-3,4-dihydroquinazolin-6-yl]oxy}phenyl)-*N'*-[4-chloro-3-(trifluoromethyl)phenyl]urea;

N-[3-(1-cyano-1-methylethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea;

10 *N*-[4-(1-cyano-1-methylethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea;

N-[3-(1,1-difluoroethyl)phenyl]-*N'*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}urea;

N-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-*N'*-[3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoromethyl)phenyl]urea;

15 *N*-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-*N'*-[6-(trifluoromethyl)pyrimidin-4-yl]urea; and


N-{4-[(3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)oxy]phenyl}-*N'*-[2-(trifluoromethyl)pyridin-4-yl]urea;

or a pharmaceutically acceptable salt thereof.

20

13. A process for preparing a compound of formula (II) or a pharmaceutically acceptable salt thereof as claimed in claim 1, which process wherein variable are, unless otherwise specified, as defined in claim 1, comprises of:

Process a) reacting an amine of the formula (II):




25

(II)


with an isocyanato of formula (III):

- 44 -



(III)


Process b) reacting a compound of formula (IV):



(IV)

5


with an compound of formula (V):



(V)


wherein L is a displaceable group;

10 Process c) reacting a compound of formula (VI):



(VI)

wherein L is a displaceable group; with an compound of formula (VII):



(VII)

15

Process d) for compounds of formula (I) wherein R⁴ is not hydrogen; reacting a compound of formula (I) wherein R⁴ is hydrogen with a compound of formula (VIII):

- 45 -




(VIII)

wherein L is a displaceable group and R^4 is not hydrogen;

Process e) for compounds of formula (I) wherein X is NR^{16} and R^{16} is $-CH_2-C_{2-6}$ alkyl

5 optionally substituted on carbon by one or more R^{21} ; reacting a compound of formula (I)

wherein X is NR^{16} and R^{16} is hydrogen with a compound of formula (IX):



(IX)

wherein R^{16} is C_{1-5} alkyl optionally substituted on carbon by one or more R^{21} ;

10 *Process f)* for compounds of formula (I) wherein X is NR^{16} and R^{16} is not hydrogen; reacting

a compound of formula (I) wherein X is NR^{16} and R^{16} is hydrogen with a compound of


formula (X):



(X)


15 wherein L is a displaceable group and R^{16} is not hydrogen;

Process g) reacting an isocyanato of the formula (XI):



(XI)

with an amine of formula (XII):



(XII)

and thereafter if necessary:

i) converting a compound of the formula (I) into another compound of the formula (I);

ii) removing any protecting groups;

25 iii) forming a pharmaceutically acceptable salt.

14. A pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in association with a pharmaceutically-acceptable diluent or carrier.
- 5 15. A compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for use as a medicament.
16. The use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for the manufacture of a medicament for the
10 production of a B-Raf inhibitory effect in a warm-blooded animal such as man.
17. The use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for the manufacture of a medicament for the production of an anti-cancer effect in a warm-blooded animal such as man.
15
18. The use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, for the manufacture of a medicament for the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in
20 the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries.
19. A method for producing a B-Raf inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective
25 amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.
20. A method for producing an anti-cancer effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount
30 of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.

21. A method of treating melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon, thyroid, lungs and ovaries, in a warm-blooded
5 animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12.

22. A pharmaceutical composition which comprises a compound of the formula (I), or a
10 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of a B-Raf inhibitory effect in a warm-blooded animal such as man.

23. A pharmaceutical composition which comprises a compound of the formula (I), or a
15 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in association with a pharmaceutically-acceptable diluent or carrier for use in the production of an anti-cancer effect in a warm-blooded animal such as man.

24. A pharmaceutical composition which comprises a compound of the formula (I), or a
20 pharmaceutically acceptable salt thereof, as claimed in any one of claims 1-12, in association with a pharmaceutically-acceptable diluent or carrier for use in the treatment of melanoma, papillary thyroid tumours, cholangiocarcinomas, colon cancer, ovarian cancer, lung cancer, leukaemias, lymphoid malignancies, carcinomas and sarcomas in the liver, kidney, bladder, prostate, breast and pancreas, and primary and recurrent solid tumours of the skin, colon,
25 thyroid, lungs and ovaries in a warm-blooded animal such as man.

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2007/001389

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D239/90 C07D239/88 C07D401/12 A61K31/517 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2006/024834 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; AQUILA BRIAN [US]; DAKIN) 9 March 2006 (2006-03-09) cited in the application claims 1,11,13-24	1,11, 13-24
A	WO 2006/024836 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; AQUILA BRIAN [US]; LYNE) 9 March 2006 (2006-03-09) cited in the application claims 1,11,13-24	1,11, 13-24
A	WO 2005/123696 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; AQUILA BRIAN [US]; DAKIN) 29 December 2005 (2005-12-29) cited in the application claims 1,7,9-20	1,11, 13-24
----- -/--		

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

17 July 2007

Date of mailing of the international search report

25/07/2007

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hass, Christian

INTERNATIONAL SEARCH REPORT

International application No
PCT/GB2007/001389

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 2006/003378 A (ASTRAZENECA AB [SE]; ASTRAZENECA UK LTD [GB]; AQUILA BRIAN [US]; IOANN.) 12 January 2006 (2006-01-12) cited in the application claims 1,7,9-26 -----	1, 11, 13-24

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB2007/001389

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 19-21 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2007/001389

Patent document cited in search report	A	Publication date		Patent family member(s)	Publication date
WO 2006024834	A	09-03-2006		AU 2005278959 A1	09-03-2006
				CA 2577275 A1	09-03-2006
				EP 1789399 A1	30-05-2007
WO 2006024836	A	09-03-2006		AR 050545 A1	01-11-2006
				AU 2005278961 A1	09-03-2006
				CA 2577278 A1	09-03-2006
				EP 1789400 A1	30-05-2007
WO 2005123696	A	29-12-2005		AU 2005254771 A1	29-12-2005
				CA 2568756 A1	29-12-2005
				EP 1761506 A1	14-03-2007
				KR 20070028536 A	12-03-2007
WO 2006003378	A	12-01-2006		AR 049662 A1	23-08-2006
				AU 2005258996 A1	12-01-2006
				CA 2570169 A1	12-01-2006
				EP 1765790 A1	28-03-2007
				KR 20070029837 A	14-03-2007